|
Biogen Idec
(NASDAQ: BIIB), a global biotechnology leader with leading products and
capabilities in oncology, neurology and immunology, is committed to transforming
scientific discovery into advances in healthcare. The company’s core
capabilities include drug discovery, research, development, manufacturing and a
global commercial infrastructure.
Biogen Idec pursues
the creativity of science with passion and discipline. For more than 25 years,
the company has grown through the discovery, development and commercialization
of its own innovative products and through strategic alliances.
Scientific
excellence that achieves new standards of care drives the company's work. Over
20 products are currently in clinical development addressing a variety of key
medical needs.
With patients in
more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:
RITUXAN® (rituximab)
was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's
lymphomas (NHL). The company co-promotes the product in the United States with
Genentech, Inc. In 2005, RITUXAN generated U.S. net sales of $1.8 billion of
which Biogen Idec recorded $709 million as co-promotion profits.
AVONEX® (Interferon
beta 1-a) is indicated for the treatment of patients with relapsing forms of
multiple sclerosis (MS) and is the most prescribed product in MS worldwide with
close to 130,000 patients on therapy. In 2005, sales of AVONEX generated
worldwide revenues of $1.54 billion.
In addition,
TYSABRI® (natalizumab) was reintroduced to the U.S. market on June 5, 2006 as a
monotherapy for relapsing forms of MS. On June 29, 2006, Biogen Idec and Elan
announced that the European Commission approved TYSABRI as a single disease
modifying therapy in highly active relapsing remitting MS. For more information,
including prescribing information and medication guide, you may also visit the
TYSABRI® (natalizumab) Information Center.
ZEVALIN® (Ibritumomab
tiuxetan), another product marketed by Biogen Idec, is a radioimmunotherapy for
use in patients with relapsed or refractory, low-grade, follicular B-cell NHL.
The product was launched in 2002.
In addition to
Biogen Idec's promising portfolio of drug candidates, the company's capabilities
and capacity for protein manufacturing are world-class in quality and scale. The
company is one of a handful of biotechnology companies that has three licensed
and dedicated biological bulk-manufacturing facilities, including its
large-scale manufacturing plant in Research Triangle Park, NC, which is one of
the world's largest cell culture facilities. An additional large-scale
manufacturing plant is under construction in Hillerød, Denmark. Biogen Idec has
sufficient commercial manufacturing capacity for its own pipeline, as well as
potential partners' products.
Biogen Idec is
headquartered in Cambridge, MA and was formed in 2003 from the merger of two of
the world's leading biotechnology companies, Biogen, Inc., founded in
Switzerland in 1978, and IDEC Pharmaceuticals Corporation, founded in San
Francisco, CA in 1985.
The company
maintains research centers of excellence in San Diego, CA and Cambridge, MA.
Biogen Idec has additional offices in Canada, Australia, Japan and throughout
Europe, including international headquarters in Zug, Switzerland and operates a
global distribution network, which covers over 70 countries. The company
currently employs approximately 3,400 people worldwide.
|
